Martin Bertschinger

Title: Martin Bertschinger: Innovator in Humanized Antibodies

Introduction

Martin Bertschinger is a notable inventor based in La Chaux-de-Fonds, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 2 patents, his work has the potential to impact various medical treatments.

Latest Patents

Bertschinger's latest patents include innovative advancements in humanized antibodies. One of his patents focuses on humanized antibodies that bind to CD19, which are crucial for targeting certain types of cancers. This invention details a humanized antibody or fragment that includes specific amino acid sequences for heavy and light chain CDRs. Another significant patent involves humanized antibodies specific for von Willebrand factor (vWF), which are designed to treat vWF mediated diseases or disorders. These patents showcase his expertise in creating targeted therapies that can improve patient outcomes.

Career Highlights

Throughout his career, Martin Bertschinger has worked with prominent companies in the pharmaceutical industry. He has been associated with Glenmark Pharmaceuticals and Ichnos Sciences, where he has contributed to various research and development projects. His experience in these organizations has allowed him to refine his skills in antibody engineering and therapeutic applications.

Collaborations

Bertschinger has collaborated with notable professionals in his field, including Stanislas Blein and Elias Lazarides. These collaborations have likely enhanced his research capabilities and broadened the impact of his inventions.

Conclusion

Martin Bertschinger is a distinguished inventor whose work in humanized antibodies is paving the way for innovative treatments in medicine. His patents reflect a commitment to advancing healthcare through biotechnology.